$1.44
-1.49 (-50.85%)
BJDX News2 articles
Bluejay Diagnostics Surges on US Manufacturing Pact, but Funding Concerns Loom
Bluejay Diagnostics (BJDX) jumped up to 213% in premarket after a US manufacturing deal with Argonaut, but the stock is volatile as Symphony awaits FDA clearance and funding is needed.
Bluejay Diagnostics Stock Surges 171% on U.S. Manufacturing Deal, FDA Hurdle Remains
Bluejay Diagnostics shares surged 171% to $5.88 after announcing a U.S. manufacturing partnership for its Symphony sepsis-testing platform, but the stock faces risks from pending FDA clearance and ongoing capital needs.